Strata Critical Medical, Inc. (SRTA) Income Statement
SRTA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSRTA revenue and net income
Where SRTA's revenue goes
2025Each bar shows an amount and its share of revenue. SRTA kept 21.0% of revenue as net income.
SRTA profit margins
SRTA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −20.7% | +10.5% | +53.1% | — |
| Gross profit | −30.2% | +22.7% | +77.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SRTA quarterly EPS vs estimates
Strata Critical Medical beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026 (estimate $0.01).
SRTA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $197.1M | $248.7M | $225.2M | $146.1M | $50.5M | $23.4M | $31.2M |
| Cost of revenue | $156.0M | $189.8M | $183.1M | $123.8M | $40.0M | $21.1M | $26.5M |
| Gross profit | $41.1M | $58.9M | $42.1M | $22.3M | $10.5M | $2.3M | $4.7M |
| Research & development | $3.1M | $3.2M | $4.6M | $5.5M | $1.7M | $861,000 | $751,000 |
| Sales, general & admin | $60.9M | $89.7M | $105.6M | $70.3M | $32.9M | $11.8M | $15.5M |
| Total operating expenses | $63.5M | $92.8M | $110.2M | $75.8M | $34.6M | $12.7M | $16.2M |
| Operating income | −$22.4M | −$33.9M | −$68.1M | −$53.5M | −$24.1M | −$10.4M | −$11.5M |
| Interest income | $4.2M | $7.2M | $8.4M | $3.4M | $460,000 | — | — |
| Interest expense | — | — | — | — | — | $1,000 | — |
| Income before taxes | −$20.1M | −$27.6M | −$57.5M | −$28.0M | −$43.7M | −$10.2M | −$10.8M |
| Income taxes | −$61.4M | −$255,000 | −$1.5M | −$772,000 | −$3.6M | −$199,000 | −$703,000 |
| Net income | $41.3M | −$27.3M | −$56.1M | −$27.3M | −$40.1M | −$10.2M | −$10.8M |
| EBITDA | −$5.7M | −$21.6M | −$50.4M | −$22.3M | −$43.1M | −$9.8M | −$11.1M |
| EPS (diluted) | −$0.35 | −$0.30 | −$0.38 | −$1.50 | −$0.57 | −$0.10 | $0.09 |
| Gross margin | 20.9% | 23.7% | 18.7% | 15.2% | 20.8% | 9.9% | 15.1% |
| Operating margin | −11.3% | −13.6% | −30.3% | −36.6% | −47.7% | −44.2% | −37.0% |
| Net margin | 21.0% | −11.0% | −24.9% | −18.7% | −79.3% | −43.4% | −34.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.5M | $67.4M | $66.8M | $49.3M | $70.8M | $54.3M | $54.4M | $74.9M | $67.9M | $51.5M | $47.5M | $71.4M |
| Cost of revenue | $57.3M | $53.3M | $55.1M | $37.7M | $53.1M | $42.3M | $41.8M | $55.0M | $51.6M | $41.4M | $38.5M | $55.9M |
| Gross profit | $15.2M | $14.1M | $11.7M | $11.6M | $17.7M | $12.0M | $12.6M | $19.8M | $16.4M | $10.1M | $9.0M | $15.6M |
| Research & development | $1.0M | $1.1M | $1.7M | $453,000 | $915,000 | $812,000 | $743,000 | $800,000 | $971,000 | $670,000 | $988,000 | $1.1M |
| Sales, general & admin | $9.2M | $15.6M | $16.8M | $16.8M | $21.8M | $18.7M | $20.2M | $22.6M | $27.5M | $19.3M | $43.7M | $22.0M |
| Total operating expenses | $20.6M | $17.1M | $18.1M | $17.2M | $22.7M | $19.6M | $21.0M | $23.4M | $28.5M | $20.0M | $44.6M | $23.0M |
| Operating income | −$5.4M | −$3.0M | −$6.4M | −$5.6M | −$5.0M | −$7.6M | −$8.4M | −$3.5M | −$12.1M | −$9.9M | −$35.6M | −$7.4M |
| Interest income | $331,000 | $473,000 | $638,000 | $1.1M | $1.2M | $1.3M | $1.6M | $1.8M | $1.8M | — | — | — |
| Income before taxes | −$10.5M | $2.4M | −$5.4M | −$9.7M | −$3.7M | −$3.5M | −$9.9M | −$2.1M | −$11.3M | −$4.3M | −$35.0M | $418,000 |
| Income taxes | — | $248,000 | $3.4M | −$64.9M | $21,000 | −$17,000 | −$105,000 | −$118,000 | $52,000 | −$84,000 | −$1.0M | $129,000 |
| Net income | −$10.5M | $2.2M | −$8.8M | $57.4M | −$3.7M | −$3.5M | −$9.8M | −$2.0M | −$11.3M | −$4.2M | −$33.9M | $289,000 |
| EBITDA | −$2.0M | $1.2M | −$558,000 | −$8.0M | −$1.9M | −$1.8M | −$8.4M | −$793,000 | −$9.7M | −$2.7M | −$33.2M | $2.3M |
| EPS (diluted) | −$0.01 | $0.04 | −$0.12 | −$0.12 | −$0.04 | −$0.07 | −$0.13 | −$0.01 | −$0.06 | −$0.10 | −$0.13 | −$0.02 |
| Gross margin | 21.0% | 21.0% | 17.5% | 23.6% | 25.1% | 22.1% | 23.2% | 26.5% | 24.1% | 19.7% | 19.0% | 21.8% |
| Operating margin | −7.5% | −4.4% | −9.6% | −11.4% | −7.0% | −14.0% | −15.4% | −4.7% | −17.9% | −19.2% | −75.1% | −10.4% |
| Net margin | −14.5% | 3.2% | −13.2% | 116.5% | −5.3% | −6.4% | −18.0% | −2.6% | −16.7% | −8.2% | −71.5% | 0.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SRTA's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SRTA financial results
In fiscal year 2025 (ended December 31, 2025), Strata Critical Medical reported revenue of $197.1 million, down 20.7% from the year before. It had net income of $41.3 million, a net profit margin of 21.0%. Diluted earnings per share came to −$0.35. Over five years revenue grew at an average rate of 53.1% a year.
See the SRTA stock overview for the latest quote and news, or the SRTA chart for price history and technical indicators.
SRTA income statement FAQ
What is Strata Critical Medical's annual revenue?
Strata Critical Medical reported total revenue of $197.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 20.7% from $248.7 million the previous year.
Is Strata Critical Medical profitable?
Yes. Strata Critical Medical reported net income of $41.3 million in fiscal 2025, a net profit margin of 21.0%; its operating margin was −11.3%.
What is Strata Critical Medical's gross margin?
Strata Critical Medical's gross margin was 20.9% in fiscal 2025: for every $100 of revenue, Strata Critical Medical kept $21 after the direct cost of its products and services.
How much does Strata Critical Medical spend on research and development?
Strata Critical Medical spent $3.1 million on research and development in fiscal 2025, 1.5% of revenue.
How fast is Strata Critical Medical growing?
Revenue grew 53.1% a year on average over the last five fiscal years, from $23.4 million to $197.1 million.
What are Strata Critical Medical's earnings per share?
Strata Critical Medical earned $-0.35 per diluted share in fiscal 2025, compared with $-0.30 a year earlier.
When will Strata Critical Medical report its next earnings?
Strata Critical Medical is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens.
When does Strata Critical Medical's fiscal year end?
Strata Critical Medical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.